Search Results

Semiconductor Research Corporation, a premier research and workforce development consortium, is announcing the launch of solicitation season.

Aprea Therapeutics, Inc. today announced that the Safety Review Committee (SRC) overseeing the ongoing ABOYA-119 clinical trial has determined that dosing of patients with ATRN-119 at 800 mg once daily (Cohort 6) can commence and that Cohort 6 is open for enrollment.

As part of the Semiconductor Research Corporation (SRC) being selected by NIST’s Advanced Manufacturing Office to define the future of Microelectronics and Advanced Packaging Technology (MAPT), Cardea Bio has been invited as a commercial semiconductor company to share their experience with integrating biology with electronics.

Semiconductor Research Corporation (SRC), a leading global semiconductor research consortium, today announced the appointment of industry veteran Todd Younkin as President and Chief Executive Officer. Younkin’s appointment was made by SRC’s Board of Directors. Younkin will start transitioning to his new role on August 18, 2020.

Twist Bioscience Corporation today announced that Steffen Hellmold, senior vice president, business development, data storage, will participate in the virtual SRC-SIA Webinar on the Decadal Plan for Semiconductors held on December 9, 2021 from 12:30pm to 2:00pm (EST).

SignalChem Biotech provides diverse recombinant Tau proteins for research, helping advance tau-targeted therapies that may modify disease progression in Alzheimer’s and related tauopathies.

Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of Nanophoton Corporation, a pioneer focused on advanced research Raman microscopy systems.

A clinical research associate is a professional who oversees clinical trials. Here are our top tips on how to become one.

Pasithea Therapeutics Corp. announced that an independent Safety Review Committee has completed its safety review of data from the first dose cohort treated in the ongoing Phase 1 clinical trial of PAS-004 in patients with MAPK pathway driven advanced solid tumors with a documented RAS, NF1 or RAF mutation or patients who have failed BRAF/MEK inhibition.